- Home
- NDLS vs GRCE Comparison
NDLS vs GRCE Comparison
Compare NDLS & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- GRCE
- Stock Information
- Founded
- NDLS 1995
- GRCE 2002
- Country
- NDLS United States
- GRCE United States
- Employees
- NDLS N/A
- GRCE N/A
- Industry
- NDLS Restaurants
- GRCE
- Sector
- NDLS Consumer Discretionary
- GRCE
- Exchange
- NDLS Nasdaq
- GRCE NYSE
- Market Cap
- NDLS 34.3M
- GRCE 34.1M
- IPO Year
- NDLS 2013
- GRCE N/A
- Fundamental
- Price
- NDLS $1.22
- GRCE $2.34
- Analyst Decision
- NDLS Strong Buy
- GRCE Strong Buy
- Analyst Count
- NDLS 2
- GRCE 1
- Target Price
- NDLS $3.00
- GRCE $12.00
- AVG Volume (30 Days)
- NDLS 164.8K
- GRCE 120.7K
- Earning Date
- NDLS 03-06-2025
- GRCE 02-13-2025
- Dividend Yield
- NDLS N/A
- GRCE N/A
- EPS Growth
- NDLS N/A
- GRCE N/A
- EPS
- NDLS N/A
- GRCE N/A
- Revenue
- NDLS $493,271,000.00
- GRCE N/A
- Revenue This Year
- NDLS $2.24
- GRCE N/A
- Revenue Next Year
- NDLS $1.18
- GRCE N/A
- P/E Ratio
- NDLS N/A
- GRCE N/A
- Revenue Growth
- NDLS N/A
- GRCE N/A
- 52 Week Low
- NDLS $0.55
- GRCE $2.13
- 52 Week High
- NDLS $2.36
- GRCE $4.97
- Technical
- Relative Strength Index (RSI)
- NDLS 43.04
- GRCE N/A
- Support Level
- NDLS $1.20
- GRCE N/A
- Resistance Level
- NDLS $1.57
- GRCE N/A
- Average True Range (ATR)
- NDLS 0.13
- GRCE 0.00
- MACD
- NDLS -0.04
- GRCE 0.00
- Stochastic Oscillator
- NDLS 4.44
- GRCE 0.00
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.